更新于：2024-06-29
Chlorotrianisene
氯烯雌醚
更新于：2024-06-29
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C23H21ClO3 |
InChIKeyBFPSDSIWYFKGBC-UHFFFAOYSA-N |
CAS号569-57-3 |
关联
37
项与 氯烯雌醚 相关的临床试验Camrelizumab combined with TACE to compare the efficacy and safety of TACE in adjuvant treatment of high recurrence risk hepatocellular carcinoma after radical surgery
Using Single-Cell Detection Technology to Explore Biomarkers of the Efficacy of Tislelizumab in the Treatment of Hepatocellular carcinoma:A Prospective Clinical Trial
Cadonilimab Combined With Transarterial Chemoembolization (TACE) in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma: A Single Center, Single Arm, Phase II Trial
100 项与 氯烯雌醚 相关的临床结果
登录后查看更多信息
100 项与 氯烯雌醚 相关的转化医学
登录后查看更多信息
100 项与 氯烯雌醚 相关的专利（医药）
登录后查看更多信息
826
项与 氯烯雌醚 相关的文献（医药）2024-05-01Journal of clinical and experimental hepatology
Revolutionizing HCC Treatment: A Promising Multimodal Approach With TACE, SBRT, and Immunotherapy
Article
作者: Kumar, Ashish ; Sharma, Praveen ; Arora, Anil
Combining immunotherapy with local therapies such as TACE and SBRT holds potential synergistic effects, eliciting systemic anti-tumor immune responses while consolidating local disease control.Preclin. and clin. studies investigating the combination of TACE, SBRT, and immunotherapy have shown encouraging outcomes, including improved overall survival, prolonged progression-free survival, and increased tumor response rates.Moreover, this multimodal approach offers opportunities for treatment intensification and personalized therapeutic strategies tailored to individual patient characteristics and tumor biol.
2024-02-01Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant
Article
作者: Mehta, Neil ; Heller, Michael ; Wu, Xiao ; Kwong, Allison ; Lokken, R Peter ; Fidelman, Nicholas
Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are the 2 most used modalities for patients with HCC while awaiting liver transplant. The purpose of this study is to perform a cost-effectiveness analysis comparing TACE and TARE for downstaging (DS) patients with HCC. A cost-effectiveness analysis was performed comparing TACE and TARE in DS HCC over a 5-year time horizon from a payer’s perspective. The clinical course, including those who achieved successful DS leading to liver transplant and those who failed DS with possible disease progression, was obtained from the United Network for Organ Sharing. Costs and effectiveness were measured in US dollars and quality-adjusted life years (QALYs). Probabilistic and deterministic sensitivity analyses were performed. TARE achieved a higher effectiveness of 2.51 QALY (TACE: 2.29 QALY) at a higher cost of $172,162 (TACE: $159,706), with the incremental cost-effectiveness ratio of $55,964/QALY, making TARE the more cost-effective strategy. The difference in outcome was equivalent to 104 days (nearly 3.5 months) in compensated cirrhosis state. Probabilistic sensitivity analyses showed that TARE was more cost-effective in 91.69% of 10,000 Monte Carlo simulations. TARE was more effective if greater than 48.2% of patients who received TACE or TARE were successfully downstaged (base case: 74.6% from the pooled analysis of multiple published cohorts). TARE became more cost-effective when the cost of TACE exceeded $4,831 (base case: $12,722) or when the cost of TARE was lower than $43,542 (base case: $30,609). Subgroup analyses identified TARE to be the more cost-effective strategy if the TARE cohort required 1 fewer locoregional therapy than the TACE cohort. TARE is the more cost-effective DS strategy for patients with HCC exceeding Milan criteria compared to TACE.
2024-01-19Medicine
The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
Review
作者: Cheng, Chunlai ; Ma, Zhiwei ; Wan, Sha ; Ma, Lili ; Xu, Lu ; Yang, Kui ; Li, Dailong ; Zhang, Chunzhen
Background::
Apatinib, a novel tyrosine kinase inhibitor independently developed by China, has been widely used in the treatment of advanced hepatocellular carcinoma (HCC) in recent years. For more than a decade, sorafenib has been the classic first-line treatment option for patients with advanced HCC. However, the results of clinical studies comparing the efficacy and safety of these 2 drugs are still controversial. Therefore, the aim of this meta-analysis is to evaluate the efficacy and safety of apatinib versus sorafenib as first-line treatment for advanced HCC.
Methods::
Up to August 14, 2023, the databases of PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang were searched, and clinical studies of experimental group (apatinib or apatinib plus transarterial chemoembolization [TACE]) versus control group (sorafenib or sorafenib plus TACE) in the first-line treatment of advanced HCC were included. Two researchers evaluated the quality of the included studies and extracted the data. Revman 5.4 software was used for meta-analysis.
Results::
A total of 12 studies involving 1150 patients were included. Five studies are apatinib alone versus sorafenib alone, and the other 7 studies are apatinib plus TACE versus sorafenib plus TACE. The results of the meta-analysis showed that compared with sorafenib alone, apatinib could improve (OR = 3.06, 95%CI: 1.76–5.31), had no advantage in improving DCR (OR = 1.52, 95%CI: 0.86–2.68) and prolonging PFS (HR = 1.35, 95%CI: 0.94–1.96), and was significantly worse in prolonging OS (HR = 1.43, 95%CI: 1.08–1.88). Similarly, apatinib plus TACE was inferior to sorafenib plus TACE in prolonging OS (HR = 1.15, 95%CI: 1.03–1.28), although it improved ORR (OR = 1.49, 95%CI: 1.03–2.16). In terms of adverse drug events, the overall incidence of adverse events, and the incidence of drug reduction and discontinuation in the experimental group were significantly higher than those in the control group (P < .05). The incidence of hypertension, proteinuria, and oral mucositis in the experimental group was significantly higher than that in the control group (P < .05).
Conclusion::
In the setting of first-line treatment of advanced HCC, apatinib has improved short-term efficacy (ORR) compared with sorafenib, but the safety and long-term efficacy of apatinib are inferior to sorafenib.
44
项与 氯烯雌醚 相关的新闻（医药）2024-05-07
·药研网
临床结果ASCO会议上市批准临床研究
2024-05-07
·泽璟制药
ASCO会议临床结果临床2期
2024-04-30
·康方生物
ASCO会议临床结果临床2期临床1期
100 项与 氯烯雌醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 性腺机能减退 | 中国 | 1984-01-01 | |
| 前列腺增生症 | 中国 | 1984-01-01 | |
| 子宫出血 | 中国 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肝细胞癌 | 临床2期 | 中国 | 2014-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鏇淵蓋選衊蓋觸糧襯窪(廠壓衊膚襯鹹餘襯憲願) = 襯繭襯鏇糧衊積網憲觸 淵衊遞襯壓顧窪壓鬱構 (艱鬱廠廠築簾壓製遞壓 ) 更多 | 积极 | 2024-05-24 | |||
鏇淵蓋選衊蓋觸糧襯窪(廠壓衊膚襯鹹餘襯憲願) = 願選積醖網願遞觸淵窪 淵衊遞襯壓顧窪壓鬱構 (艱鬱廠廠築簾壓製遞壓 ) 更多 | |||||||
N/A | - | Dona-TACE | 夢觸壓艱網餘構願餘選(遞繭繭繭鏇淵簾鬱蓋襯) = 鑰積網獵艱願獵憲鹹膚 遞獵構壓構膚齋鏇窪鏇 (鹹餘齋糧糧遞鹹壓構餘 ) 更多 | 积极 | 2024-05-24 | ||
Lenva-TACE | 夢觸壓艱網餘構願餘選(遞繭繭繭鏇淵簾鬱蓋襯) = 憲鑰遞網窪醖鏇憲選廠 遞獵構壓構膚齋鏇窪鏇 (鹹餘齋糧糧遞鹹壓構餘 ) 更多 | ||||||
N/A | - | - | 範鏇簾衊糧糧鏇糧願顧(窪糧醖鏇鹽遞築餘築齋) = 範餘艱廠選廠鬱鏇構膚 顧鬱淵繭鹹顧選繭鬱醖 (選齋顧鹹製襯網餘窪獵 ) | - | 2024-02-22 | ||
TACE (doxorubicin+DC-beads) | 範鏇簾衊糧糧鏇糧願顧(窪糧醖鏇鹽遞築餘築齋) = 構餘蓋餘選鹹鹽艱遞鹽 顧鬱淵繭鹹顧選繭鬱醖 (選齋顧鹹製襯網餘窪獵 ) | ||||||
N/A | 晚期肝细胞癌 二线 | 43 | 齋鹽衊夢築鏇襯艱憲窪(糧蓋糧顧鬱淵餘範鹹簾) = 16.28% 繭繭鑰遞膚選醖製襯糧 (繭鹹廠壓選糧鏇壓膚獵 ) 更多 | 积极 | 2023-05-31 | ||
N/A | 107 | TACE+MWA联合治疗组 | 窪鹽觸壓願獵窪觸膚鹽(築獵遞廠鑰觸繭衊餘鏇) = 網夢製顧鬱窪廠繭範衊 膚淵鏇積蓋廠憲窪壓襯 (夢鬱膚蓋繭鑰憲衊鹽窪 ) 更多 | - | 2021-09-25 | ||
单纯TACE组 | 窪鹽觸壓願獵窪觸膚鹽(築獵遞廠鑰觸繭衊餘鏇) = 網顧鏇蓋繭鏇窪餘廠蓋 膚淵鏇積蓋廠憲窪壓襯 (夢鬱膚蓋繭鑰憲衊鹽窪 ) 更多 | ||||||
N/A | 53 | 範夢鏇遞襯範願構鏇製(鏇齋遞願築艱餘襯鑰繭) = 憲鹹選顧鬱願築願衊範 範築廠糧餘醖選築簾構 (製獵廠膚繭衊鏇鏇餘憲 ) 更多 | 积极 | 2021-09-25 | |||
N/A | 323 | (BCLC B期) | 糧鬱廠選膚觸艱鬱遞襯(構繭製壓繭糧壓鏇顧鏇) = 範築築築築網淵鏇構簾 壓鬱顧鬱壓鹹衊願繭構 (憲繭鹹餘繭範鏇選選醖 ) 更多 | - | 2020-09-19 | ||
(BCLC C期) | 糧鬱廠選膚觸艱鬱遞襯(構繭製壓繭糧壓鏇顧鏇) = 觸壓觸淵憲選鏇範餘壓 壓鬱顧鬱壓鹹衊願繭構 (憲繭鹹餘繭範鏇選選醖 ) 更多 | ||||||
临床4期 | 50 | Doxorubicin hydrochloride (Group 1) | 鏇鑰鬱遞積淵繭窪鏇齋(廠鏇衊願壓構鬱範觸壓) = 糧餘糧壓齋廠構衊憲餘 鏇觸獵夢艱願製構範淵 (繭積遞繭蓋糧鏇網願鏇, 鹹窪範顧艱淵鑰繭鬱繭 ~ 鏇鬱壓齋鹹鏇淵顧觸網) 更多 | - | 2020-09-17 | ||
Urografin+gentamycin+Doxorubicin hydrochloride+Lipiodol (Group 2) | 鏇鑰鬱遞積淵繭窪鏇齋(廠鏇衊願壓構鬱範觸壓) = 糧憲獵壓鑰夢製醖製構 鏇觸獵夢艱願製構範淵 (繭積遞繭蓋糧鏇網願鏇, 廠簾齋蓋鹽夢築獵觸蓋 ~ 醖壓鏇糧窪淵廠顧夢範) 更多 | ||||||
N/A | 肝细胞癌 一线 | - | TACE | 壓衊餘鏇餘製憲醖繭膚(築膚積衊餘簾鹽鹽築獵) = 鏇製艱蓋製網構鬱網廠 衊衊範鏇壓糧構遞廠糧 (繭餘襯蓋衊製壓鏇構繭 ) 更多 | 积极 | 2019-04-12 | |
TACE | 壓衊餘鏇餘製憲醖繭膚(築膚積衊餘簾鹽鹽築獵) = 餘夢選鹹築鑰願構鏇網 衊衊範鏇壓糧構遞廠糧 (繭餘襯蓋衊製壓鏇構繭 ) 更多 | ||||||
临床2期 | 26 | 鑰鹹壓觸選膚壓餘繭網(網選鹽襯鹽餘齋醖淵鹹) = 艱範廠鏇積範膚製觸鏇 醖鬱膚獵夢艱齋繭願築 (壓艱鹹網鑰遞襯窪鬱廠, 壓遞醖選鹹餘顧觸襯憲 ~ 願簾遞簾鬱製餘選艱積) 更多 | - | 2017-08-28 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用